Viltolarsen

维托拉生

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameViltolarsen
Drug Alias Name维托拉尔森DMD therapeutics - NCNP/Nippon ShinyakuExon 53 skipping antisense oligonucleotide - Nippon Shinyaku/National Center of Neurology and PsychiatryExon 53 skipping DMD therapeutic - Nippon Shinyaku/National Center of Neurology and PsychiatryViltepso +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystroglycan stimulants
TargetsDystroglycanDystrophin pre-mRNA
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsMuscular Dystrophy, Duchenne
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2020/03/25
Country/TerritoryCzechiaCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNippon Shinyaku Co LtdNational Center Of Neurology And Psychiatry
China Registration ClassN/A

Develop Information

Active CompaniesNs Pharma IncNippon Shinyaku Co Ltd
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeJ05AB
Related LinksWikipediaDrugBankKEGG